Table 3.
Univariate and multivariate analyses of association between clinical parameters and time to progressive disease.
| Clinical features | Patient numbers | Univariate | Multivariate | ||
| HR† (95% CI‡) |
P-value | HR† (95% CI‡) |
P-value | ||
|
| |||||
| Stage (I vs II vs III) | 13 : 27 : 65 | - | 0.008 ∗ | 1.668 (1.040-2.676) |
0.035 ∗ |
|
| |||||
| Tumor site (Upper vs Middle vs Lower) | 28 : 48 : 29 | - | 0.514 | - | - |
|
| |||||
| Gender (Male vs Female) | 98 : 7 | 0.388 (0.069-0.736) |
0.014 ∗ | 2.184 (0.947-5.040) |
0.068 |
|
| |||||
| Age (≥ vs <60 years old) | 40 : 65 | 0.766 (0.434-1.303) |
0.309 | - | - |
|
| |||||
| Surgery (Yes vs No) | 38 : 67 | 1.850 (1.090-2.996) |
0.022 ∗ | 0.413 (0.225-0.760) |
0.005 ∗ |
|
| |||||
| Radiotherapy (4000~5000cGy vs >5000cGy) | 40 : 65 | 0.779 (0.469-1.301) |
0.348 | - | - |
|
| |||||
| Days from diagnosis to initial treatment (< v.s ≥29) | 57 : 48 | 1.251 (0.758-2.062) |
0.382 | - | - |
|
| |||||
| Days from diagnosis to complete treatment (< v.s ≥69) | 54 : 51 | 0.821 (0.493-1.354) |
0.433 | - | - |
|
| |||||
| Hematologic Markers | |||||
|
| |||||
| Platelet count of pre-treatment (≥ vs <300,000/μL) | 34 : 71 | 0.580 (0.303-0.956) |
0.035 ∗ | 1.326 (0.681-2.582) |
0.409 |
|
| |||||
| Platelet count of post-treatment (≥ vs <300,000/μL) | 9 : 96 | 0.456 (0.105-0.960) |
0.042 ∗ | 2.538 (1.024-6.291) |
0.045 ∗ |
|
| |||||
| MPV§ (≥ vs <9.8fl) | 51 : 50& | 0.849 (0.508-1.411) | 0.522 | - | - |
|
| |||||
| Hemoglobin (≥ vs <14g/dL) | 17 : 88 | 1.402 (0.754-2.477) |
0.303 | - | - |
|
| |||||
| White blood count (≥ vs <10,000/μL) | 12 : 93 | 0.648 (0.230-1.516) |
0.274 | - | - |
|
| |||||
| Absolute Neutrophil count (≥ vs <4483/μL) | 53 : 52 | 0.740 (0.444-1.218) |
0.232 | - | - |
|
| |||||
| Neutrophil percentage (≥ vs <73.4%) | 53 : 52 | 0.809 (0.490-1.332) |
0.403 | - | - |
|
| |||||
| Absolute Monocyte count (≥ vs <449/μL) | 53 : 52 | 0.961 (0.583-1.583) |
0.874 | - | - |
|
| |||||
| Monocyte percentage (≥ vs <7%) | 53 : 52 | 0.803 (0.486-1.321) |
0.385 | - | - |
|
| |||||
| Absolute lymphocyte counts (≥ vs <1042/μL) | 53 : 52 | 1.615 (0.987-2.725) |
0.056 | - | - |
|
| |||||
| Lymphocyte percentage (≥ vs <16%) | 53 : 52 | 1.838 (1.134-3.160) |
0.015 ∗ | 0.336 (0.053-2.131) |
0.250 |
|
| |||||
| Biomarker of Inflammation | |||||
|
| |||||
| Platelet to-ALC∧ ratio (≥ vs <236) | 53 : 52 | 0.535 (0.309-0.865) | 0.012 ∗ | 0.854 (0.399-1.826) |
0.685 |
|
| |||||
| Platelet-to-Lymphocyte(%) ratio (≥ vs <14605) | 53 : 52 | 0.511 (0.296-0.826) |
0.007 ∗ | 0.971 (0.412-2.291) |
0.947 |
|
| |||||
| Neutrophil-to-Lymphocyte ratio (≥ vs <4.35) | 53 : 52 | 0.571 (0.339-0.933) |
0.026 ∗ | 0.453 (0.077-2.678) |
0.385 |
†HR, hazard ratio; ‡CI, confidence interval; §MPV, mean platelet volume; ∧ALC, absolute lymphocyte count; &no data of 4 patients.